Vanda Pharmaceuticals Inc. (VNDA) SEC Filing 8-K Material Event for the period ending Wednesday, February 24, 2021

Vanda Pharmaceuticals Inc.

CIK: 1347178 Ticker: VNDA

View differences made from one to another to evaluate Vanda Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vanda Pharmaceuticals Inc..


Assess how Vanda Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Vanda Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: VNDA
CIK: 1347178
Form Type: 8-K Corporate News
Accession Number: 0001193125-21-055675
Submitted to the SEC: Thu Feb 25 2021 7:01:31 AM EST
Accepted by the SEC: Thu Feb 25 2021
Period: Wednesday, February 24, 2021
Industry: Pharmaceutical Preparations
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: